Antivirals and resistance: Influenza virus

Michael G. Ison*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

159 Scopus citations


Influenza causes annual epidemics of respiratory viral infections are associated with significant morbidity and mortality. Influenza vaccines have been shown to reduce the risk of infection and mitigate against some of the virus' sequellae. Likewise, two classes of antivirals, the adamantanes (amantadine and rimantadine) and the neuraminidase inhibitors (laninamivir, oseltamivir, peramivir, and zanamivir) are currently approved for the prevention and treatment of influenza; several other classes of antivirals and immune modulators are also currently under investigation. One of the greatest challenges to our armamentarium of antivirals is the emergence of resistant mutants. In this paper, we will review the currently approved and investigational antiviral agents and the mechanisms of resistance that impact their activity.

Original languageEnglish (US)
Pages (from-to)563-573
Number of pages11
JournalCurrent Opinion in Virology
Issue number6
StatePublished - Dec 2011

ASJC Scopus subject areas

  • Virology


Dive into the research topics of 'Antivirals and resistance: Influenza virus'. Together they form a unique fingerprint.

Cite this